Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures: 2021-2024

Historic Gains from Sales and Divestitures for Protagonist Therapeutics (PTGX) over the last 3 years, with Dec 2024 value amounting to $316,748.

  • Protagonist Therapeutics' Gains from Sales and Divestitures was N/A to $75,500 in Q3 2025 from the same period last year, while for Sep 2025 it was $75,500, marking a year-over-year change of. This contributed to the annual value of $316,748 for FY2024, which is 4.68% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Gains from Sales and Divestitures of $316,748 as of FY2024, which was up 4.68% from $302,582 recorded in FY2023.
  • Protagonist Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $316,748 during FY2024, with a 5-year trough of $78,165 in FY2021.
  • For the 2-year period, Protagonist Therapeutics' Gains from Sales and Divestitures averaged around $309,665, with its median value being $309,665 (2023).
  • Data for Protagonist Therapeutics' Gains from Sales and Divestitures shows a peak YoY grew of 4.68% (in 2024) over the last 5 years.
  • Protagonist Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $78,165 in 2021, then reached $302,582 in 2023, then increased by 4.68% to $316,748 in 2024.